& Freytag, B
Diversified Biopharma sector at J.P Morgan
The STEP trials for semaglutide 2.4 mg (Wegovy) showed: Average weight loss of approximately 15% of body weight over 68 weeks One-third of participants lost 20% or more of body weight Significant reductions in waist circumference, blood pressure, and cardiovascular risk markers The SURMOUNT trials for tirzepatide (Zepbound) showed even more impressive results: Average weight loss of 20-25% at the highest dose (15 mg) over 72 weeks More than half of participants lost 20% or more of body weight Significant improvements in type 2 diabetes markers, blood pressure, and lipid profiles The head-to-head comparison is clear
Always discuss changes with a qualified medical professional who can account for your complete health picture, including factors the plotter cannot model like your medical history, concurrent medications, and lab results
PlexusDx clinicians monitor stool patterns and recommend dietary or supplement adjustmentslike soluble fiber or pancreatic enzymesif needed
Collectively, these findings demonstrated that sulforaphane exert neuroprotective effect involving Nrf2-dependent reductions in oxidative stress, mTOR-dependent inhibition of neuronal apoptosis and the restoration of normal autophagy
